Use of a compound of formula (I): wherein R.sub.1 is selected from alkyl, alkoxy, aryloxy, alkylthio, arylthio, aryl, halogen, CN, NR.sub.6R.sub.7, NR.sub.5COR.sub.6, NR.sub.5CONR.sub.6R.sub.7, NR.sub.5CO.sub.2R.sub.8 and NR.sub.5SO.sub.2R.sub.8; R.sub.2 is selected from heteroaryl attached via an unsaturated carbon; R.sub.3 is selected from H, alkyl, halogen, OR.sub.5, SR.sub.5 and NR.sub.6R.sub.7; R.sub.4 is selected from H, acyclic alkyl, CONR.sub.6R.sub.7, CONR.sub.5NR.sub.6R.sub.7, COR.sub....

Compounds of the formulas ##SPC1## In which R.sub.1 stands for branched alkyl, alkenyl or cycloalkyl having at least three carbon atoms or hydroxyalkyl. R' stands for free or substituted amino, hydrazino, halogen or free or etherified mercapto, and R" stands for hydrogen, alkyl or for R' for example: the 2-ispropyl-4-mercapto-pyrazolo[3,4-d]pyrimidine. Use: Coronary dilatating, diuretic, analgetic or antibacterial agents.

The present invention describes new homo or heterodimer prodrugs wherein both active monomeric units are compounds of the formula: ##STR00001## where R.sub.1 and R.sub.2 are each independently --H, --C.sub.1 C.sub.6 alkyl --C.sub.1 C.sub.6OH, or --C.sub.1 C.sub.6NHR', wherein R' is --H, or --C.sub.1 C.sub.6 alkyl, R.sub.3 is: ##STR00002## where R.sub.4 and R.sub.5 are defined in the description. The monomeric units are coupled to each other via a labile carbonate (--O--COO--), carbamate (--O--CO...

A method for preparing pyrazolopyrimidinone derivatives and their pharmaceutically acceptable salts having efficacy on the treatment of impotence, one of male sexual dysfunctions. The method comprises the steps of: a) chlorosulfonating a pyrazolamide compound to obtain a chlorosulfonated compound; b) reacting the chlorosulfonated compound of step (a) with a primary amine to obtain a sulfonamide compound and c) performing an intramolecular cyclization of the sulfonamide compound of step (b) to pr...

The pyrazoles and pyzazolopyrimidines of the formula ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4 and A are as defined herein, have corticotropin releasing factor (CRF) antagonist activity. As such, they are effective in the treatment of a wide range of diseases including stress-related illnesses.

A polymorph of 1-{6-ethoxy-5-[3-ethyl-6,7-dihydro-2-(2-methoxyethyl)-7-oxo-2H-pyrazolo[4, 3-d]pyrimidin-5-yl]-3-pyridylsulfonyl}-4-ethylpiperazine.

A reactive oxygen generating enzyme inhibitor with NO donor bioactivity, e.g., nitrated allopurinol, e.g., 1,5-bis(3-nitrooxypropyyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidine-4-one is useful to treat heart failure, stable angina, ischemic disorder, ischemic reperfusion injury, atherosclerosis, sickle cell disease, diabetes, Alzheimer's disease, Parkinson's disease, ALS and asthma and to obtain proper contraction of heart, skeletal and smooth muscle. Where the disorder is heart failure, administr...

The present invention relates to 5-aminomethylpyrazolo[4,3-d]pyrimidines of the general formula (I) ##STR00001## in which the radicals R.sup.1 to R.sup.6 have the meaning indicated in the text. The compounds show phosphodiesterase V inhibition and can be employed for the treatment of conditions of the cardiovascular system and for the treatment of potency disorders.

A turbine, driven from the exhaust gases of the internal combustion engine, and having a speed-flow volume and pressure differential characteristic which is only little speed-dependent drives a Foettinger hydrodynamic torque converter which has a pump element which is highly speed-dependent, a radial flow turbine which is only little speed-dependent, and a guide vane element, the radial flow turbine of the fluid coupling driving a displacement-type rotary compressor so that, even at low engine s...

Novel derivatives of 1-phenyl-1H-pyrazolo[3,4-d]pyrimidine substituted at the 4-position of the pyrimidine ring are provided. A typical example is 1-phenyl-1H-pyrazolo[3,4-d]pyrimidine-4-carbonitrile. The compounds exhibit excellent anti-carcinogenic activities as evidenced by the animal test with mice.